Selpercatinib for RET-Altered Thyroid Cancer and MTC: Lori Wirth, MD

In this interview, Lori Wirth, MD, speaks with i3 Health about selpercatinib (RetevmoTM, Eli Lilly), which was recently approved by the FDA for the treatment of patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC), advanced/metastatic RET-mutant medullary thyroid cancer (MTC), and advanced/metastatic RET fusion-positive thyroid cancer. Dr. Wirth, Medical Director of the Center for Head and Neck Cancers at Massachusetts General Hospital and first author of the phase 1/2...
Continue reading

Best Practices in Thyroid Cancer Management With Jochen H. Lorch, MD, MS

Thyroid cancer is one of the most prevalent cancers in the United States. An estimated 56,870 new cases are diagnosed annually, and 2,010 people die of the disease. Thyroid cancer is typically more aggressive in men than women and becomes increasingly lethal in those older than age 40. The dearth of data from well-designed trials has led to confusion over the optimal management strategies for individual patients. In this interview, Jochen Lorch, MD, MS, Assistant Professor of Medicine at Harvard...
Continue reading

Copyright © 2020 Oncology Data Advisor. All rights reserved.